π Tender Overview
Understanding And Exploiting Epigenetic Regulation In Car T Cell Therapy
Delving Into The Epigenetics Of Car T Cell Therapychimeric Antigen Receptor T Cells (Car Ts) Are A New Approach For Boosting A PatientβS Immune System To Fight Cancer. Car Ts Are Patient Cells Engineered To Detect Specific Antigens On Cancer Cells And Destroy Them. The Scope Of The Eu-Funded Epi-Cart Project Is To Increase Our Understanding Of Car Ts From An Epigenetic Perspective, Something That HasnβT Been Investigated Before. Researchers Will Undertake Epigenetic And Transcriptomic Profiling Of These Cells After Transplantation. Linking This Information With Immune Regulation Will Uncover Epigenetic Drivers Of Car T Cell Response And Help Optimise This Immunotherapy For Solid Tumours.
Funded Under
Excellent Science - European Research Council (Erc)
Total Cost
β¬ 1 999 913,00
Eu Contribution
β¬ 1 999 913,00
Coordinated By
Cemm - Forschungszentrum Fuer Molekulare Medizin Gmbh
Austria